Delcath Systems to Hold Q2 2024 Earnings Call

Delcath Systems, Inc., a prominent interventional oncology firm, is set to host a conference call on August 5, 2024, at 4:30 PM Eastern Time. The focus of this call will be the company's financial results for the second quarter, which concluded on June 30, 2024. Interested participants are encouraged to join the call a few minutes prior to its commencement.

Delcath Systems specializes in addressing primary and metastatic liver cancers through interventional oncology techniques. The company's flagship products are the HEPZATO KIT™ and the CHEMOSAT® Hepatic Delivery System, both designed to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure and associated side effects.

The HEPZATO KIT, a combination of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS), is a key product in the company's portfolio. This system facilitates the surgical isolation of the liver, allowing for the filtration of hepatic venous blood during the administration and washout of melphalan. The localized delivery of a high dose of melphalan through the HDS aims to achieve significant tumor responses with minimal liver toxicity and reduced systemic exposure.

In the United States, the HEPZATO KIT is recognized as a combination drug-device product and is approved by the FDA for sale as a drug. The product is specifically indicated for the liver-directed treatment of adult patients with metastatic uveal melanoma (mUM) who have unresectable hepatic metastases involving less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to sites that are amenable to resection or radiation. It is crucial to review the full prescribing information for the HEPZATO KIT, which includes a boxed warning.

In Europe, the Hepatic Delivery System is marketed as the CHEMOSAT Hepatic Delivery System for Melphalan. It is regulated as a Class III medical device and has been approved for sale. The CHEMOSAT system has been employed in numerous major medical centers across Europe for percutaneous hepatic perfusion procedures to treat various liver cancers.

By focusing on innovative liver-directed treatments, Delcath Systems aims to provide effective therapeutic options for patients with challenging liver cancers. The upcoming conference call will provide an opportunity for stakeholders to gain insights into the company's latest financial performance and developments in their treatment offerings.